Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
NCT07535008 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2026-04-23
Summary
This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.
Conditions
- Chronic Graft Versus Host Disease
- Acute Graft Versus Host Disease
- Hematopoietic and Lymphatic System Neoplasm
Interventions
- PROCEDURE
-
Dental Cleaning
Dental cleaning
- PROCEDURE
-
Dental Plaque sampling
Ancillary studies
Sponsors & Collaborators
-
Fred Hutchinson Cancer Center
lead OTHER
Principal Investigators
-
Armin Rashidi, MD, PhD · Fred Hutch/University of Washington Cancer Consortium
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-22
- Primary Completion
- 2028-04-30
- Completion
- 2029-04-30
Countries
- United States
Study Locations
More Related Trials
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
NCT06649201 ·Status: RECRUITING
-
Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
NCT00209352 ·Status: COMPLETED ·Phase: PHASE3
-
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
NCT02108522 ·Status: COMPLETED ·Phase: NA
-
T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation
NCT03180216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant
NCT03883906 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
NCT04230356 ·Status: RECRUITING ·Phase: PHASE2
-
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
NCT02231853 ·Status: TERMINATED ·Phase: PHASE1
-
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
NCT00986557 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
NCT05305040 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
NCT01241344 ·Status: COMPLETED ·Phase: PHASE2
-
Administration of Virus-Specific Cytotoxic T-Lymphocytes
NCT00590083 ·Status: COMPLETED ·Phase: PHASE1
-
Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
NCT04778618 ·Status: UNKNOWN ·Phase: PHASE2
-
Abatacept s.c. for aGVHD Prevention in Haplo-HCT
NCT04686929 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
NCT02007356 ·Status: RECRUITING ·Phase: PHASE2
-
Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT
NCT02873325 ·Status: TERMINATED
-
Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation
NCT02351427 ·Status: UNKNOWN ·Phase: PHASE3
-
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
NCT01713400 ·Status: COMPLETED ·Phase: PHASE2
-
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
NCT00711035 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
NCT07246031 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
NCT04293042 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
NCT07150468 ·Status: COMPLETED
-
ATG Individualized Dosing Model in URD-PBSCT.
NCT06572462 ·Status: RECRUITING ·Phase: PHASE2
-
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
NCT04017338 ·Status: UNKNOWN ·Phase: PHASE3
-
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
NCT03533816 ·Status: RECRUITING ·Phase: PHASE1
-
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
NCT04832607 ·Status: RECRUITING ·Phase: PHASE3